Dr. Leamon earned an ACS-certified B.S. degree in Chemistry from Baldwin Wallace University and a Ph.D. in Chemistry from Purdue University.
He began his professional career in the pharmaceutical industry where he conducted targeted drug delivery research in the fields of peptide, oligonucleotide, liposome, and DNA drug delivery for GlaxoSmithKline, Inc. and Ionis Pharmaceuticals.
He later helped to establish Endocyte, Inc. where he was a named executive officer. While there he led the Company’s targeted drug discovery division, which included oncology, inflammation, and polycystic kidney disease programs, for 20 years until its 2018 acquisition by Novartis.
Following a 3-year integration, Dr. Leamon left Novartis to become Chief Scientific Officer at Fusion Pharmaceuticals to help advance a diverse pipeline of targeted radiopharmaceuticals for cancer therapy.
Dr. Leamon has published over 90 articles and is an inventor on more than 60 issued or submitted patents. Importantly, in 2015 he was the recipient of the 2015 American Chemical Society, George and Christine Sosnovsky Award for Cancer Research.
To date, Dr. Leamon’s efforts have yielded 8 clinically investigated imaging and therapeutic agents for the treatment of cancer.
